AU2018256840A1 - Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab) - Google Patents

Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab) Download PDF

Info

Publication number
AU2018256840A1
AU2018256840A1 AU2018256840A AU2018256840A AU2018256840A1 AU 2018256840 A1 AU2018256840 A1 AU 2018256840A1 AU 2018256840 A AU2018256840 A AU 2018256840A AU 2018256840 A AU2018256840 A AU 2018256840A AU 2018256840 A1 AU2018256840 A1 AU 2018256840A1
Authority
AU
Australia
Prior art keywords
dose
antibody
seq
weeks
pediatric patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018256840A
Other languages
English (en)
Inventor
Maria Rosario
Michael A. Shetzline
William R. Treem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2018256840A1 publication Critical patent/AU2018256840A1/en
Priority to AU2025202525A priority Critical patent/AU2025202525A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018256840A 2017-04-28 2018-04-26 Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab) Abandoned AU2018256840A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202525A AU2025202525A1 (en) 2017-04-28 2025-04-09 Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
US62/492,031 2017-04-28
PCT/US2018/029579 WO2018200818A2 (en) 2017-04-28 2018-04-26 Method of treating pediatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202525A Division AU2025202525A1 (en) 2017-04-28 2025-04-09 Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)

Publications (1)

Publication Number Publication Date
AU2018256840A1 true AU2018256840A1 (en) 2019-11-07

Family

ID=62455814

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018256840A Abandoned AU2018256840A1 (en) 2017-04-28 2018-04-26 Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
AU2025202525A Pending AU2025202525A1 (en) 2017-04-28 2025-04-09 Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202525A Pending AU2025202525A1 (en) 2017-04-28 2025-04-09 Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)

Country Status (13)

Country Link
US (1) US20200179486A1 (https=)
EP (1) EP3615071A2 (https=)
JP (2) JP2020517671A (https=)
KR (2) KR20250134146A (https=)
CN (1) CN110612120A (https=)
AR (1) AR111491A1 (https=)
AU (2) AU2018256840A1 (https=)
BR (1) BR112019022268A2 (https=)
CA (1) CA3061320A1 (https=)
IL (1) IL270201B1 (https=)
MX (4) MX2019012749A (https=)
TW (2) TWI811216B (https=)
WO (1) WO2018200818A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
US20220408780A1 (en) * 2020-02-11 2022-12-29 The E. Wolfson Medical Center A method effective for treating ulcerative colitis
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025177055A1 (en) * 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Combination therapy for treating inflammatory bowel disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
KR20170120601A (ko) * 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
BR112018068625A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro

Also Published As

Publication number Publication date
JP2020517671A (ja) 2020-06-18
IL270201B1 (en) 2026-01-01
EP3615071A2 (en) 2020-03-04
JP2023113655A (ja) 2023-08-16
AR111491A1 (es) 2019-07-17
TW202342102A (zh) 2023-11-01
IL270201A (https=) 2019-12-31
MX2024003906A (es) 2024-04-23
MX2024012972A (es) 2024-11-08
WO2018200818A3 (en) 2018-12-06
MX2019012749A (es) 2020-02-03
AU2025202525A1 (en) 2025-05-01
CA3061320A1 (en) 2018-11-01
WO2018200818A2 (en) 2018-11-01
RU2019138312A3 (https=) 2022-02-03
BR112019022268A2 (pt) 2020-05-19
US20200179486A1 (en) 2020-06-11
RU2019138312A (ru) 2021-05-28
WO2018200818A9 (en) 2019-01-17
MX2024003905A (es) 2024-04-23
CN110612120A (zh) 2019-12-24
KR20250134146A (ko) 2025-09-09
TWI811216B (zh) 2023-08-11
KR20190141148A (ko) 2019-12-23
TW201842932A (zh) 2018-12-16

Similar Documents

Publication Publication Date Title
AU2025202525A1 (en) Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
AU2016323447B2 (en) Anti-pro/latent-Myostatin antibodies and uses thereof
JP6297088B2 (ja) Ｐｃｓｋ９アンタゴニスト
KR20210005169A (ko) 최적화된 항tl1a 항체
JP2021191779A (ja) イヌインターロイキン４受容体アルファに対する抗体
KR102148063B1 (ko) 베타7 인테그린 길항제를 투여하는 방법
US20240309104A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2016105572A1 (en) PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
US20250243289A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
JP6942053B2 (ja) 原発性硬化性胆管炎を治療する方法
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
WO2024173861A2 (en) Anti-tl1a antibody compositions and methods of treating skin
WO2024186859A2 (en) Anti-tl1a antibody compositions and methods of treatment for sarcoidosis
RU2778567C2 (ru) Способ лечения педиатрических расстройств/заболеваний
US20230220053A1 (en) ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
TW202448933A (zh) 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
HK40076541A (en) Methods of administering beta7 integrin antagonists
HK40008722A (en) Methods of administering beta7 integrin antagonists

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted